2023 年 5 月 24 日，苏州富士莱医药股份有限公司（以下简称“富士莱医药”）旗下全资子公司苏州鲲泰生物科技有限公司（以下简称“鲲泰生物 ”）正式启动运营，富士莱医药董事长兼总经理钱祥云及相关本部人员莅临参观调研，鲲泰生物法定代表人卞爱进等人陪同。
鲲泰生物专注于高端特色原料药领域，致力于为国内外客户提供小分子特色原料药和医药中间体，同时发展并战略布局寡核苷酸药物领域，为客户提供个性化定制合成和生产服务。卞爱进指出，鲲泰生物的正式运营标志着富士莱医药在战略转型升级上迈出了重要的一步，为公司带来更多的发展机遇和市场竞争力。董事长兼总经理钱祥云先生代表集团公司对鲲泰生物的正式运营表示祝贺，同时也提出了殷切的期望，鲲泰生物是富士莱未来业绩发展的第二增长曲线，希望大家发挥自己的专业技能和创新精神，勇于尝试新的思路和方法，不断追求科学突破和技术创新，为鲲泰生物的发展贡献自己的智慧和力量。
On May 24, 2023, Suzhou Kuntai Biotechnology Co., Ltd. (hereinafter referred to as "Kuntai Bio"), a wholly-owned subsidiary of Suzhou Fujilai Pharmaceutical Co., Ltd. (hereinafter referred to as "Fujilai Pharmaceutical"), officially launched its operation.
Focusing on the field of high-end specialty APIs, Kuntai Biotech is committed to providing small molecule specialty APIs and pharmaceutical intermediates for domestic and foreign customers, and at the same time developing and strategically deploying the field of oligonucleotide drugs to provide customers with personalized customized synthesis and production services. Bian Aijin pointed out that the official operation of Kuntai Biotech marks an important step in the strategic transformation and upgrading of Fujilai Pharmaceutical, bringing more development opportunities and market competitiveness to the company. Mr. Qian Xiangyun, chairman and general manager of the board of directors, congratulated the official operation of Kuntai Biotechnology on behalf of the group company, and also put forward ardent expectations, Kuntai Bio is the second growth curve of Fujilai's future performance development, and hopes that everyone will give full play to their professional skills and innovative spirit, have the courage to try new ideas and methods, constantly pursue scientific breakthroughs and technological innovation, and contribute their wisdom and strength to the development of Kuntai Biotech.
